ライフサイエンスコーパス: seroconversion

1 Viral pathogens were associated with lower seroconversion.

2 quartile range 6.14-22.02 years) after HBeAg seroconversion.

3 end point was the rate of HIV type 1 (HIV-1) seroconversion.

4 re reconstructed from estimated dates of HIV seroconversion.

5 oup, and there was a trend toward more-rapid seroconversion.

6 ability of the host may have large impact on seroconversion.

7 atment might be helpful for predicting HBeAg seroconversion.

8 most mutations disappeared about the time of seroconversion.

9 azard model, adjusting for gender and age at seroconversion.

10 inflammatory phase before spontaneous HBeAg seroconversion.

11 significantly associated with delayed HBeAg seroconversion.

12 increase in titer from baseline constituted seroconversion.

13 ear cells (PBMCs) and sigmoid biopsies after seroconversion.

14 10 years, and 1.4% (0.9-1.5) 15 years after seroconversion.

15 nt stopped with loss of HBsAg and anti-HBsAg seroconversion.

16 ical patients reexposed to heparin developed seroconversion.

17 hich gel users are closely monitored for HIV seroconversion.

18 ed articles were included in the analysis of seroconversion.

19 -progression during the first 10 years after seroconversion.

20 inflammatory phase was associated with HBeAg seroconversion.

21 persistent high-level shedding, viremia, and seroconversion.

22 duced human immune responses following HBeAg seroconversion.

23 to identify the associated factors with HDV seroconversion.

24 of suicidal attempt in a woman following HIV seroconversion.

25 p<0.0001) in the past 6 months predicted HIV seroconversion.

26 y expanded CD8(+) T cells was observed after seroconversion.

27 not hepatitis B surface antigen clearance or seroconversion.

28 revalent or incident HSV-2 infection and HIV seroconversion.

29 ine aminotransferase normalization and HBeAg seroconversion.

30 ore they developed detectable parasitemia or seroconversion.

31 HIV incidence was estimated from observed seroconversions.

32 estimate based on prospectively observed HIV seroconversions.

33 ression did not change beyond 10 years after seroconversion (0.28 [95%CI 0.26-0.31] per person-year a

34 0.26-0.31] per person-year at 10 years after seroconversion, 0.24 [0.19-0.29] per person-year at 15 y

35 tive individuals at 6 months demonstrated 12 seroconversions (1 individual was lost to follow-up).

36 ractional dose of intradermal IPV gave lower seroconversion (10%-40%), but after 2 doses seroconversi

37 At 10 years since HIV seroconversion, 283 individuals had LTNP, of whom 202 su

38 ng day 42 antibody titer of 40 or greater or seroconversion (a minimum 4-fold increase to titer >/=40

39 s, predicted amino acid changes, and time of seroconversion, a finding consistent with immune selecti

40 were the most prevalent mutants before HBeAg seroconversion, acting as markers of HBeAg seroconversio

41 any detectable HPV at the visit prior to HIV seroconversion (adjusted odds ratio, 1.02; 95% confidenc

42 iew and meta-analysis of studies documenting seroconversion after 1 or 2, full or fractional (1/5) do

43 HBV genotype C (hazard ratio = 4.40), HBeAg seroconversion after 18 years of age (hazard ratio = 2.4

44 Fifteen patients who achieved HBeAg seroconversion after a mean duration of 19 +/- 14 (range

45 0.59 years), and 75 subjects developed HBeAg seroconversion after antiviral therapy.

46 erence in day 42 hemagglutination inhibition seroconversion after mixing adjuvant with either the fir

47 after the 1(st) OCV dose; with no additional seroconversion after the 2(nd) dose.

48 uction, as measured by ELISpot assay and IgG seroconversion against all antigens.

49 There was no concomitant seroconversion against GI VLPs, indicating a highly geno

50 Seroconversion against H1N1 was strongly associated with

51 The rVP1 ELISA detected seroconversion against SVA in clinically affected and no

52 We defined a seroconversion algorithm (ie, a >/=4-fold increase in th

53 sk behaviour during screening and subsequent seroconversion among placebo recipients using a Poisson

54 ndomized and nonrandomized studies reporting seroconversions among uninfected animals exposed to HIV

55 by Western blot testing, there were 16 HSV-2 seroconversions among women assigned to tenofovir gel as

56 We discovered that, prior to seroconversion, an early potent, largely type I interfer

57 HPV type-specific seroconversion analysis was done for participants who we

58 lowing GII-4 NO infection, genotype-specific seroconversion and a corresponding increase in blocking

59 ong-term progression-free survival after HIV seroconversion and aimed to identify factors associated

60 included noninferiority of rubella antibody seroconversion and evaluating rotavirus IgA/IgG seroresp

61 pient immunosuppression delayed or prevented seroconversion and extended the duration of viraemia.

62 tecavir plus tenofovir combination, anti-HBe seroconversion and HBsAg loss were observed, while the t

63 Both were predictors of spontaneous HBsAg seroconversion and HBV recovery (odds ratios 4.0 and 26.

64 ion, and are predictive of spontaneous HBsAg seroconversion and HBV recovery.

65 sion than TDF alone, although rates of HBeAg seroconversion and hepatitis B surface antigen loss were

66 to establish chronic infection with delayed seroconversion and hepatitis.

67 Primary endpoints were seroconversion and median antibody titres to type 2 poli

68 entify changes that could be detected before seroconversion and positivity for disease-associated aut

69 isition of antiviral control before anti-HBs seroconversion and represent the groundwork for future s

70 The primary endpoints were HIV-1 seroconversion and safety.

71 different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs

72 After both the doses, seroconversion and seroprotection were >90% for JENVAC.

73 For SA-14-14-2, seroconversion and seroprotection were 57.69% and 77.56%

74 antibody titres at day 28 and percentages of seroconversion and seroprotection, all determined by hae

75 n T1D progressors in the time window between seroconversion and T1D diagnosis, accompanied by spikes

76 between antibiotic use in early life before seroconversion and the development of autoimmunity.

77 ociation was found between timing of PEP and seroconversion and the use of tenofovir compared with ot

78 inical signs, infected guinea pigs developed seroconversion and the viral antigen was detected in lun

79 Secondary outcomes were seroconversion and titres to serotype 2 and faecal shedd

80 rses for several weeks followed by a delayed seroconversion and viral clearance.

81 10(6) FFU H77S.2 virus resulted in immediate seroconversion and, following an unusual 4- to 6-week de

82 oviruses (NPEVs) and diarrhea on the odds of seroconversion and/or vaccine virus shedding.

83 lence and measles, rubella, and yellow fever seroconversion, and (1/3) log2 for log2-transformed anti

84 Time from HCV infection to seroconversion, and from seroconversion to seroreversion

85 Importantly, HBeAg loss, HBeAg seroconversion, and HBsAg loss only occurred in patients

86 duce severity of liver injury, achieve HBeAg seroconversion, and prevent development of liver fibrosi

87 tart of immune-clearance phase, age at HBeAg seroconversion, and serum IL-10 and IL-12 levels are ass

88 infection (AOR=1.82; 95% CI 1.18, 2.81), HCV seroconversion (AOR=3.05; 95% CI 1.40, 6.66), and recent

89 By day 28, all the vaccine recipients had seroconversion as assessed by an enzyme-linked immunosor

90 -26) and, in 20 (87%) of 23 women, prevented seroconversion, as shown with western blotting.

91 The primary outcome was HSV2 seroconversion, assessed annually.

92 Although seroconversion at 10 weeks did not meet significance in

93 compare antirotavirus immunoglobulin A (IgA) seroconversion at 18 weeks in the 6/10/14 arm to the cum

94 red over 18 months) was reviewed to identify seroconversions at 12 HDUs.

95 he age of 48 mo and hepatitis B e Ag (HBeAg) seroconversion before the age of 10 y predicted spontane

96 s 4-6 weeks post-vaccination and the rate of seroconversion between baseline and post-vaccination ser

97 ive outcomes such as pathogen incrimination, seroconversion, biomarkers, and anthropometry can be hel

98 he incidence of HIV on the basis of observed seroconversion data, participant-reported use of ART, pa

99 Seroconversion dates were estimated for 4079 patients on

100 based on the time interval between estimated seroconversion dates.

101 s obtained every 6 months were evaluated for seroconversion, defined as a 4-fold increase in immunogl

102 HBeAg loss and seroconversion did not differ between groups; only 1 pat

103 sessed in this study in early life or before seroconversion did not influence the risk of developing

104 ants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.

105 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1

106 HBeAg seroconversion during childhood predicts a lower risk of

107 ive at enrolment and those with HCV antibody seroconversion during follow-up (1996 to 2012) were test

108 children were associated with delayed HBeAg seroconversion during long-term follow-up, and more HBV

109 gle 10 mug of CHIKV iDNA plasmid resulted in seroconversion, elicitation of neutralizing antibodies,

110 Estimated CD4 counts at seroconversion for a typical individual declined from ab

111 The second vaccination resulted in a 100% seroconversion for all participants in the candidate vac

112 Plasma was collected before seroconversion for cases.

113 Primary infection was diagnosed based on seroconversion for HCMV and/or HCMV immunoglobulin M-pos

114 individuals meeting the primary endpoint of seroconversion for poliovirus types 1, 2, and 3 was alre

115 The primary outcome was seroconversion for poliovirus types 1, 2, and 3 with tit

116 similar antibody ontogenies and patterns of seroconversion for S1, N, M, and WV antigens.

117 s significantly reduced the odds of per-dose seroconversion for type 1 poliovirus (odds ratio [OR] 0.

118 ority for bOPV groups versus mOPV1 groups in seroconversion for type 1 poliovirus, and for bOPV1 shor

119 was the proportion of infants with antibody seroconversion for type 1, type 2, and type 3 poliovirus

120 Seroconversion for type 2 was noted in 16 infants (9%, 5

121 Seroconversion for type 3 was noted in 175 infants (94%,

122 Seroconversion for type-1 poliovirus was recorded in 183

123 In groups 1, 2, and 3, the IgA seroconversion frequencies among participants with IgA l

124 A third dose of HRV resulted in increased seroconversion frequencies and GMCs, compared with 2 dos

125 , 6, 9, 12, 24, 36, 48, and >48 months after seroconversion from 95 women in the CAPRISA 004 trial (3

126 dividuals with well-estimated dates of HIV-1 seroconversion from the CASCADE Collaboration a network

127 d serum antirotavirus immunoglobulin A (IgA) seroconversion (>/=20 U/mL) and geometric mean concentra

128 i-dengue virus (DENV) immunoglobulin M (IgM) seroconversion has been the reference standard for dengu

129 2.46), and lamivudine therapy prior to HBeAg seroconversion (hazard ratio = 1.42) were predictors of

130 g seroconversion, acting as markers of HBeAg seroconversion (hazard ratios = 2.75 and 4.50; P = .01 a

131 on spontaneous hepatitis B e antigen (HBeAg) seroconversion, HBV biosynthesis, and the human immune r

132 8 weeks in the 6/10/14 arm to the cumulative seroconversion (highest result at 14 or 18 weeks) in the

133 sistent DMPA use might increase risk of HSV2 seroconversion; however, study power was low.

134 Four (21%) reported a symptomatic HCV seroconversion illness, including 2 with jaundice.

135 Intraoperative heparin induced EIA seroconversion in 11/17 (65%) patients (immunoglobulin G

136 ted antigen dose with MF59 adjuvant produced seroconversion in 59% of participants.

137 nts (immunoglobulin G [IgG]>IgA>IgM) and SRA seroconversion in 8/17 (47%), whereas none of 3 medical

138 The algorithm detected seroconversion in 94% of individuals with a diagnosis of

139 ral course of hepatitis B surface Ag (HBsAg) seroconversion in chronic hepatitis B virus (HBV) infect

140 the age of 10 y predicted spontaneous HBsAg seroconversion in chronically HBV-infected patients (odd

141 h severe inflammation that facilitates HBeAg seroconversion in earlier life.

142 t documented seroconversion or of documented seroconversion in patients with a compatible clinical sy

143 Seroconversion in the 6/10 arm at 14 weeks (post hoc) wa

144 Seroconversion in the 6/10/14 arm was 36.7% (95% CI, 29.

145 The main outcome of this study was HIV seroconversion in the intent-to-treat population as esti

146 We observed 1619 HIV seroconversions in 17 016 individuals, over 60 349 perso

147 We noted HSV2 seroconversions in 70 (10%) women.

148 ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person

149 the intervention group, 102 participants had seroconversion (incidence density 18.45 per 100 person-y

150 Seroconversion increased with age at administration.

151 to a family member with T1D, autoantibody at seroconversion, INS gene (rs1004446_A), and non-HLA gene

152 Seroconversion is associated with influenza-specific T-h

153 esting and awareness of atypical patterns of seroconversion is highly recommended.

154 These results challenge the hypothesis that seroconversion is the only reliable correlate of protect

155 ut also a protracted cytokine response after seroconversion, marked by the production of monocyte and

156 The primary study outcome was seroconversion (minimum titer of 1:40 and >/=4-fold rise

157 Neither seroconversion nor viremia could be demonstrated in any

158 Nevertheless, seroconversion occurred at a rate of 65% against the Oga

159 The peak seroconversion occurred at day 29 in 62 participants (62

160 Type 2 seroconversion occurred in 19 of 198 infants (9.6%, 95%

161 HBeAg seroconversion occurred in 3 patients (5%), all in the T

162 Spontaneous HBeAg seroconversion occurred in 359 subjects at a median age

163 f 3.75 microg plus the MF59 adjuvant, day 42 seroconversion occurred in 58 participants (59%; 95% CI,

164 H7N9 vaccine plus the MF59 adjuvant, day 42 seroconversion occurred in 81 participants (82%; 95% CI,

165 All seroconversions occurred during the first 2 weeks after

166 Eight HIV seroconversions occurred overall, with four documented d

167 g DMPA had an adjusted hazard ratio for HSV2 seroconversion of 2.26 (95% CI 1.09-4.69; p=0.029) compa

168 nced corpus gastritis, increased the odds of seroconversion of IgG S. Typhi flagella antibody (adjust

169 al Inaba vaccine strain CVD 103-HgR, elicits seroconversion of vibriocidal antibodies (a correlate of

170 t HSV-2 cases were identified by evidence of seroconversion on an HSV-2 IgG enzyme-linked immunosorbe

171 There were no seroconversions on PrEP and 7 virological failures on ea

172 The primary end point was seroconversion or a >/=4-fold rise in antibody titer.

173 (92%) of 24 patients with data available had seroconversion or a four-fold increase in antibody titre

174 nce of erythema migrans and documentation of seroconversion or a positive real-time blood PCR.

175 sence of erythema migrans without documented seroconversion or of documented seroconversion in patien

176 and lack of rotavirus immunoglobulin A (IgA) seroconversion (OR, 1.95; P = .018) were associated with

177 nt diarrhea significantly inhibited per-dose seroconversion overall (OR 0.61 [0.38-0.87]).

178 ciated with CD4 cell count at 10 years after seroconversion (p < 0.0001) and HIV RNA load at 10 years

179 ated with lower CD4 counts at 10 years after seroconversion (p < 0.0001).

180 to 35 HBeAg-positive patients without HBeAg seroconversion (P < 0.001 for months 3 and 6).

181 < 0.0001) and HIV RNA load at 10 years after seroconversion (p = 0.005), but not age (p = 0.544), mod

182 12 (13%) assigned monotherapy achieved HBeAg seroconversion (P = 0.036).

183 0.621), sex (p = 0.676), or calendar year of seroconversion (p = 0.397).

184 act with their stable partner 4 months after seroconversion (P<0.001), which may have lowered the ris

185 tibody was the first-appearing indication of seroconversion [P = 0.006]) were statistically significa

186 ommercially available kits and verified with seroconversion panels, the WHO HBeAg standard, rHBeAg, a

187 We found an atypical seroconversion pattern, with initially only gp160 antibo

188 We report an incidence of 30.07 seroconversions per 100 child-years.

189 n during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with

190 on during 917 person-years of follow-up (6.1 seroconversions per 100 person-years).

191 The seroconversion percentages were significantly higher at

192 After seroconversion, perforin expression was downregulated in

193 clustering included younger age, recent HCV seroconversion, prevalent HIV infection, and recent syri

194 Seroconversion proportions among women at week 28 for HP

195 riority were predefined as <5% difference in seroconversion rate and <2-fold difference in geometric

196 Other outcomes were seroconversion rate and mean titers, influenza A-specifi

197 nstrated the potential of using altitude and seroconversion rate as measures of malaria transmission

198 The jet injector group met the seroconversion rate criterion for non-inferiority for th

199 ncluded if the lower two-sided 90% CI of the seroconversion rate difference between IPV-Al and IPV wa

200 of the three 95% CIs for the strain-specific seroconversion rate differences was less than 10 percent

201 B strains (upper bound of the 95% CI of the seroconversion rate differences were 6.0% for A/H1N1, 7.

202 The HIV seroconversion rate was 6.4 (95% CI: 1.3-18.7) per 100 p

203 The cumulative HBeAg seroconversion rate was significantly lower in the vacci

204 B strain, respectively) resulting into lower seroconversion rates (P</=0.01) as compared with HC (40.

205 infected women, HIV-infected women had lower seroconversion rates (ranging from 63%-92% vs 36%-40%),

206 For AMA-1, the seroconversion rates (SCRs) ranged from 0.121 (Ngodhe) t

207 es were reduced by co-administration but the seroconversion rates achieved non-inferiority in both ca

208 at baseline, anti-rotavirus immunoglobulin A seroconversion rates after 3 vaccine doses differed sign

209 d increase against influenza B and (2) lower seroconversion rates against influenza H1N1 than noncolo

210 Seroconversion rates against polioviruses types 1 and 3

211 ferior to the 3D_M0,1,6 schedule in terms of seroconversion rates and 3D/2D geometric mean titers for

212 Overall seroconversion rates and geometric mean neutralization t

213 ion experienced (1) lower seroprotection and seroconversion rates and lower hemagglutination-inhibiti

214 An inverse correlation was found between seroconversion rates and number of previous vaccinations

215 inferiority were hemagglutination inhibition seroconversion rates and postvaccination geometric mean

216 At 1 month after vaccination, seroconversion rates and the proportion of participants

217 Annual seroconversion rates based on a sero-catalytic model tha

218 ll dose cohorts after one immunisation, with seroconversion rates of 44% (n=4) in the low-dose group,

219 doses of bOPV or tOPV elicited type 1 and 3 seroconversion rates of at least 97.7%.

220 Subcutaneous vaccination resulted in higher seroconversion rates than transcutaneous vaccination but

221 before rotavirus vaccination could raise low seroconversion rates that correlate with the vaccine's i

222 In groups receiving adjuvanted formulations, seroconversion rates were >/=85.7%, seroprotection rates

223 Seroconversion rates were 16.7%, 41.7%, and 13.3%, respe

224 Seroconversion rates were especially low in those on MMF

225 the modified intention-to-treat population, seroconversion rates were significantly higher in the bo

226 uals from northeast Tanzania using altitude, seroconversion rates, and parasite rates as proxies of h

227 Seroconversion rates, based on antibody prevalence to Pl

228 Abs to some antigens showed high seroconversion rates, reaching maximal levels early in c

229 High doses of MMF (>/= 2 g/d) led to lower seroconversion rates, smaller increase in H1N1-specific

230 4 count <200 cells/microL had lower rates of seroconversion rates.

231 bsolute differences in three strain-specific seroconversion rates.

232 study of 131 Zimbabwean women in whom HIV-1 seroconversion recently occurred were tested for detecti

233 Hepatitis B envelope antigen (HBeAg) seroconversion represents an endpoint of treatment of ch

234 Seroconversion risk data were pooled using random-effect

235 rance/loss (RR = 1.9, 95% CI 1.7-3.1), HBeAg seroconversion (RR = 2.1, 95% CI 1.3-3.5), alanine amino

236 uppression (RR = 2.9, 95% CI 1.8-4.6), HBeAg seroconversion (RR = 2.1, 95% CI 1.4-3.3), and hepatitis

237 ed immunosorbent assay titers over baseline (seroconversion [SCN]) 42 days after immunization.

238 This study also investigated the seroconversion sensitivity of the assay.

239 strategies to those with HIV and recent HCV seroconversion should be explored, given an increased li

240 ables including comorbidities and time since seroconversion, significant, direct negative effects of

241 Delayed seroconversion, slightly elevated circulating liver enzy

242 f the Short Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) trial.

243 tion of samples collected >2 years after HCV seroconversion that were misclassified as recent; (3) sa

244 B virus reactivation referred to as "reverse seroconversion." There remain many uncertain areas that

245 om before the development of autoantibodies (seroconversion) through the diagnosis of diabetes.

246 in British Columbia, Canada, with documented seroconversion time frames.

247 Our results show that seroconversion to a salivary molecule, rLinB-13, is a ma

248 The estimated time from seroconversion to AIDS and AIDS-related death was 5.0 an

249 gression was measured as time from estimated seroconversion to AIDS and AIDS-related death.

250 ta were derived from the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) col

251 Percentage of seroconversion to all (ID 14% vs IM 15%; P = .8) or at l

252 Seroconversion to at least 1 of 3 influenza antigens was

253 Seroconversion to each poliovirus type was seen in 100%

254 In the 47 patients analyzed, seroconversion to H1N1 antigen was demonstrated in 34%.

255 Seroconversion to heterologous A/H3N2, for example, was

256 Vaccinated animals showed a strong seroconversion to LppQ, but they exhibited significantly

257 Additionally, patients who showed early seroconversion to neutralizing IgG responses had better

258 weeks after vaccination with mIPV2HD or IPV, seroconversion to poliovirus type 2 was recorded in 107

259 eiving fractional doses, cumulative two-dose seroconversion to poliovirus types 1, 2, and 3 occurred

260 IgG titers in pre-dose 1 sera of infants and seroconversion to RV1 post-dose 1.

261 om HCV infection to seroconversion, and from seroconversion to seroreversion, was estimated using the

262 Although seroconversion to the heterologous GII-4-1999 variant wa

263 cted in nearly all subjects, suggesting that seroconversion to these proteins may be a sensitive indi

264 spectively, the proportions of children with seroconversion to type 1 poliovirus were 166 (98.8%) of

265 Proportions of seroconversion to type-1 poliovirus were 107/135 (79%, 9

266 rity (within a 20% margin) between groups in seroconversion to type-1 poliovirus.

267 le antigens was observed in 10 patients, and seroconversions to single antigens occurred in 11 patien

268 umoral immunity (neutralising antibodies-ie, seroconversion) to all three serotypes and intestinal im

269 every visit, 2 had low concentrations at the seroconversion visit, and 1 had variable concentrations.

270 cted in none of the transgender women at the seroconversion visit, six (18%) of 33 seronegative trans

271 184V or I mutations that were predominant at seroconversion waned to background levels within 24 week

272 Seroconversion was 100% in Vi-TT and 88.6% in Vi-PS part

273 f 132 women with HSV2-seropositive partners, seroconversion was 36.4 per 100 person-years in consiste

274 idence of seroreversion within 3 years after seroconversion was 37% (95% confidence interval, 18%-66%

275 Median time from HCV infection to seroconversion was 74 days (IQR, 47-125 days).

276 The weighted probability of durable HBeAg seroconversion was 91.9% and 88.0% at 12 and 24 months,

277 tibody titre by PRNT60 was 250 (176-355) and seroconversion was 95.7% (85.5-98.8).

278 dpoint titre was 1624 (95% CI 1146-2302) and seroconversion was 95.7% (95% CI 85.5-98.8); the geometr

279 HBV-infected subjects with and without HBsAg seroconversion was also analyzed.

280 The clinical course of spontaneous HBsAg seroconversion was assessed in 296 chronically HBV-infec

281 HIV seroconversion was associated with raised genital inflam

282 seroconversion (10%-40%), but after 2 doses seroconversion was comparable to that with full-dose IPV

283 Rotavirus seroconversion was defined as a 4-fold rise in immunoglo

284 model, higher HIV RNA load at 10 years after seroconversion was independently associated with loss of

285 Spontaneous HBsAg seroconversion was not related to sex, HBV genotype, or

286 the subgroup of patients 18 to 64 years old, seroconversion was significantly greater with adjuvanted

287 agnitude of the seroresponse and the rate of seroconversion were also blunted.

288 Lower serum zinc level and lack of IgA seroconversion were associated with increased risk of RV

289 Risk factors for seroconversion were frequency of injection, homelessness

290 In addition, no HIV seroconversions were detected among prison inmates.

291 No other HIV seroconversions were identified during the study.

292 Of these, 145 HIV seroconversions were observed, resulting in a weighted H

293 4,427 person-years; among these persons, 931 seroconversions were observed.

294 t was to be the strongest predictor of HBeAg seroconversion, when compared to levels of HBV DNA, HBsA

295 with or without hepatitis B surface antibody seroconversion, which is associated with improved clinic

296 ls and HLA-DR expression on B cells captured seroconversion with high specificity.

297 more, the D-ELISA was efficient in detecting seroconversion with vectored vaccine, using recombinant

298 dules compared with the all-IPV schedule for seroconversion (within a 10% margin) and antibody titres

299 und in HBeAg-positive patients who had HBeAg seroconversion without HBsAg clearance.

300 Following HIV type 1 (HIV-1) seroconversion, women have up to 40% lower HIV loads and